[go: up one dir, main page]

AU2001231137A1 - Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors - Google Patents

Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors

Info

Publication number
AU2001231137A1
AU2001231137A1 AU2001231137A AU3113701A AU2001231137A1 AU 2001231137 A1 AU2001231137 A1 AU 2001231137A1 AU 2001231137 A AU2001231137 A AU 2001231137A AU 3113701 A AU3113701 A AU 3113701A AU 2001231137 A1 AU2001231137 A1 AU 2001231137A1
Authority
AU
Australia
Prior art keywords
protease
treatment
neuraminidase inhibitors
neuropsychiatric disease
neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231137A
Inventor
William J. Freed
Marquis P. Vawter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001231137A1 publication Critical patent/AU2001231137A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001231137A 2000-01-25 2001-01-25 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors Abandoned AU2001231137A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17797100P 2000-01-25 2000-01-25
US60177971 2000-01-25
PCT/US2001/002417 WO2001054729A1 (en) 2000-01-25 2001-01-25 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors

Publications (1)

Publication Number Publication Date
AU2001231137A1 true AU2001231137A1 (en) 2001-08-07

Family

ID=22650670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231137A Abandoned AU2001231137A1 (en) 2000-01-25 2001-01-25 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors

Country Status (2)

Country Link
AU (1) AU2001231137A1 (en)
WO (1) WO2001054729A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314476D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
DE102006036373A1 (en) * 2006-08-02 2008-02-07 Johannes-Gutenberg-Universität Mainz Medicines for LCT poisoning
CN116687923A (en) * 2023-06-15 2023-09-05 苏州志恒生物科技有限公司 Application of ritonavir or derivative thereof in preparation of medicines for treating mental disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3026864B2 (en) * 1991-09-18 2000-03-27 メルシャン株式会社 New sesquiterpene derivatives
EP0751940B1 (en) * 1994-03-25 1999-05-12 Gruppo Lepetit S.P.A. Sesquiterpenic derivatives
WO1999034789A1 (en) * 1998-01-08 1999-07-15 Hoffman Keith B Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host
US6566498B1 (en) * 1998-02-06 2003-05-20 Human Genome Sciences, Inc. Human serine protease and serpin polypeptides
CA2226919A1 (en) * 1998-02-13 1999-08-13 Peter Sonderegger Neuroserpin

Also Published As

Publication number Publication date
WO2001054729A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2003221786A1 (en) Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
IL160295A0 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
PL375052A1 (en) Pharmaceutical pig and method of use
IL157577A0 (en) Disposable underpants and method of providing the same
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU1166502A (en) Human ect2 and methods of use
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
NO20024528L (en) Protease inhibitor, pharmaceutical composition and use of the compound
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU3622600A (en) Metalloproteinases and methods of use therefor
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU6536200A (en) Proteases and protease inhibitors
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2002346594A1 (en) Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU2001289936A1 (en) Use of amino acids for treating pain
AU2001231137A1 (en) Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
AU2003286068A1 (en) Process for the treatment of pig manure and the use thereof
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias